This antibody detects CD229 / LY9 at C-term. At least three isoforms of SLAMF3 are known to exist. This antibody is predicted to not cross-react with other protein family members.
Kreuzreaktivität (Details)
Species reactivity (tested):Human, mouse, rat
Aufreinigung
Affinity chromatography purified via peptide column
Immunogen
18 amino acid peptide near the carboxy terminus of human CD229
Optimal working dilution should be determined by the investigator.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Buffer
PBS containing 0.02 % sodium azide
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handhabung
Avoid repeated freezing and thawing.
Lagerung
4 °C/-20 °C
Informationen zur Lagerung
Store at 2 - 8 °C for up to three months or (in aliquots) at -20 °C for longer.
Target
LY9 (CD229)
(Lymphocyte Antigen 9 (CD229))
Andere Bezeichnung
CD229 / LY9
Hintergrund
The signaling lymphocyte-activation molecule family member 3 (SLAMF3), also known as LY9 and CD229, is a cell surface receptor that is expressed on T and B lymphocytes and belongs to the CD150/SLAMF1 receptor family. SLAMF3 was identified through a yeast two-hybrid screening in which SLAMF3 bound to the X-linked lymphoproliferative disease gene product SAP, suggesting that in activated T cells, SLAMF3 signaling can be triggered SAP. Its expression on the cell surface appears to be regulated via its interaction with the clathrin-associated adaptor complex 2 (AP-2). Despite its similarity to SLAMF1 in structure and interactions with SAP, SLAMF3-deficient mice do not exhibit phenotypic characteristics associated with SLAMF1- and SAP-deficient mice, suggesting that SLAMF3 plays other roles in T cell activation.Synonyms: Ly-9, Lymphocyte antigen 9, T-lymphocyte surface antigen Ly-9